Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 4Recruiting 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Carcinoma, Hepatocellular 27Parkinson Disease 4, Autosomal Dominant Lewy Body 23Neoplasms 14Melanoma 8Endometrial Neoplasms 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 7Thyroid Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Cholangiocarcinoma 6Stomach Neoplasms 4Recurrence 4Carcinoma 4Biliary Tract Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Paraganglioma, Extra-Adrenal 2Osteosarcoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Liver Neoplasms 2Glioma 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, Hurthle cell 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Recurrence × lenvatinib × Clear all
NCT04447755 2025-10-03

E7080-G000-231

Merck Sharp & Dohme LLC

Phase 2 Completed
127 enrolled 29 charts

Recurrence

NCT04154189 2024-07-22

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Eisai Inc.

Phase 2 Completed
81 enrolled 22 charts
Sarcoma

Recurrence, Osteosarcoma

NCT06253364 2024-03-13

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Tongji Hospital

Completed
462 enrolled

Recurrence

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Eisai Inc.

Phase 1/2 Completed
64 enrolled 29 charts
CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡